The Role of Affect Regulation and Self-presentation in the Expressive Writing Intervention

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2010 by University of Toronto.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
University of Toronto
ClinicalTrials.gov Identifier:
NCT00831727
First received: January 28, 2009
Last updated: April 14, 2010
Last verified: April 2010

January 28, 2009
April 14, 2010
February 2009
December 2009   (final data collection date for primary outcome measure)
Posttraumatic Stress Diagnostic Scale [ Time Frame: Initial session; One month follow-up ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00831727 on ClinicalTrials.gov Archive Site
  • Difficulties in Emotion Regulation Scale [ Time Frame: Initial session; One month follow-up ] [ Designated as safety issue: No ]
  • Pennebaker Inventory of Limbic Languidness [ Time Frame: Initial session; One month follow-up ] [ Designated as safety issue: No ]
  • Beck Depression Inventory, Second Edition [ Time Frame: Initial session; One month follow-up ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
The Role of Affect Regulation and Self-presentation in the Expressive Writing Intervention
Examining Potential Moderators and Mediators in the Expressive Writing Intervention: The Role of Affect Regulation and Self-presentation.

The purpose of the present study is twofold. First, we will attempt to examine the role that emotion regulation and self-presentation play as potential moderators in the expressive writing paradigm. We hypothesize that expressive writing participants who demonstrate greater abilities to regulate their emotions at baseline will improve more on our outcome measures. We also hypothesize that those expressive writing participants who demonstrate higher levels of self-presentation at baseline will improve less on our outcome measures.

The second aim of the study has two related objectives. First, we will attempt to investigate whether the expressive writing intervention can increase and enhance an individual's emotion regulation abilities. Related to this, we will then go on to examine whether emotion regulation can be looked at as a potential mechanism of action in the expressive writing procedure. Related to these two objectives, we hypothesize that in comparison to the control group, participants in the expressive writing condition will show increases in their ability to regulate their emotions from baseline to four week follow up. Moreover, we predict that greater gains in emotion regulation abilities for the expressive writing participants will be significantly related to greater gains in outcome measures.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Posttraumatic Stress Disorders
  • Behavioral: Expressive Writing
    Participants will write about their experienced trauma for 20 minutes on each of three consecutive days using techniques associated with expressive writing
    Other Name: Emotional writing
  • Behavioral: Control
    Participants will write as factually as possible about an assigned trivial topic for 20 minutes on each of three consecutive days
  • Experimental: Expressive Writing
    Intervention: Behavioral: Expressive Writing
  • Placebo Comparator: Control
    Intervention: Behavioral: Control
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
90
February 2010
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Fluent in English
  • Previously experienced trauma (not current or ongoing; excluding bereavement)
  • Currently experiencing trauma-related distress

Exclusion Criteria:

  • Currently involved in psychotherapy
  • Currently taking psychotropic medications
  • Imminent threat to self or others
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00831727
23614, SSHRC 767-2007-2210-4
No
Justin M. Mattina, University of Toronto
University of Toronto
Not Provided
Study Director: Jeanne C Watson, Ph.D. University of Toronto
Principal Investigator: Justin M Mattina, M.A. University of Toronto
Principal Investigator: Jonathan J Danson, B.A. University of Toronto
University of Toronto
April 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP